Structural, conformational and thermodynamic aspects of groove-directed-intercalation of flavopiridol into DNA.
Ray B, Agarwal S, Lohani N, Rajeswari MR, Mehrotra R.
J Biomol Struct Dyn · journal article · DOI 10.1080/07391102.2015.1118708 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för alvocidib. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
17 träffarClinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.
Zeidner JF, Karp JE.
Leuk Res · review; journal article · DOI 10.1016/j.leukres.2015.10.010Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.
Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE.
Haematologica · clinical trial, phase ii; comparative study; research-article; multicenter study; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.3324/haematol.2015.125849Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model.
Kwak MS, Yu SJ, Yoon JH, Lee SH, Lee SM, Lee JH, Kim YJ, Lee HS, Kim CY.
J Cancer Res Clin Oncol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1007/s00432-015-1990-6Investigation of the cytotoxic effect of flavopiridol in canine lymphoma cell lines.
Ema Y, Igase M, Takeda Y, Yanase T, Umeki S, Hiraoka H, Okuda M, Mizuno T.
Vet Comp Oncol · comparative study; journal article · DOI 10.1111/vco.12130Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer.
Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, De Siervi A.
Curr Pharm Biotechnol · retracted publication; research support, non-u.s. gov't; journal article · DOI 10.2174/138920101606150407114407The effect of organic anion-transporting polypeptides 1B1, 1B3 and 2B1 on the antitumor activity of flavopiridol in breast cancer cells.
Brenner S, Riha J, Giessrigl B, Thalhammer T, Grusch M, Krupitza G, Stieger B, Jäger W.
Int J Oncol · research support, non-u.s. gov't; journal article · DOI 10.3892/ijo.2014.2731Induced growth inhibition, cell cycle arrest and apoptosis in CD133+/CD44+ prostate cancer stem cells by flavopiridol.
Soner BC, Aktug H, Acikgoz E, Duzagac F, Guven U, Ayla S, Cal C, Oktem G.
Int J Mol Med · research-article; journal article · DOI 10.3892/ijmm.2014.1930Sequential combination of flavopiridol with Taxol synergistically suppresses human ovarian carcinoma growth.
Song Y, Xin X, Zhai X, Xia Z, Shen K.
Arch Gynecol Obstet · research support, non-u.s. gov't; journal article · DOI 10.1007/s00404-014-3408-0Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.
Jones JA, Rupert AS, Poi M, Phelps MA, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JC.
Am J Hematol · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1002/ajh.23568Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors.
Sekine C, Sugihara T, Miyake S, Hirai H, Yoshida M, Miyasaka N, Kohsaka H.
J Immunol · research support, non-u.s. gov't; journal article · DOI 10.4049/jimmunol.180.3.1954Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation In vivo after carotid injury in the rat.
Ruef J, Meshel AS, Hu Z, Horaist C, Ballinger CA, Thompson LJ, Subbarao VD, Dumont JA, Patterson C.
Circulation · research support, u.s. gov't, p.h.s.; journal article · DOI 10.1161/01.cir.100.6.659Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
Bible KC, Kaufmann SH.
Cancer Res · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal articleFlavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.
Drees M, Dengler WA, Roth T, Labonte H, Mayo J, Malspeis L, Grever M, Sausville EA, Fiebig HH.
Clin Cancer Res · journal articleFlavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy.
Sedlacek H, Czech J, Naik R, Kaur G, Worland P, Losiewicz M, Parker B, Carlson B, Smith A, Senderowicz A, Sausville E.
Int J Oncol · journal article · DOI 10.3892/ijo.9.6.1143Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.
Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland PJ.
Biochem Biophys Res Commun · comparative study; journal article · DOI 10.1006/bbrc.1994.1742Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275.
Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, Czech J, Naik R, Sausville E.
J Natl Cancer Inst · journal article · DOI 10.1093/jnci/84.22.1736